We claim:

1. A combination comprising a pure 5-HT_6 receptor antagonist and an NMDA receptor antagonist wherein the pure 5-HT_6 receptor antagonist is selected from,
1-[(2-Bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1H-indole;
1-[(4-Fluorophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1H-indole; and
1-[(4-Isopropylphenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1H-indole;
or a pharmaceutically acceptable salt thereof.

2. The combination as claimed in claim 1, wherein the pure 5-HT_6 receptor antagonist is,
1-[(2-Bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1H-indole or a pharmaceutically acceptable salt thereof.

3. The combination as claimed in claim 1 or claim 2, wherein the pharmaceutically acceptable salt of the pure 5-HT_6 receptor antagonist is selected from,
1-[(2-Bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1H-indole dimesylate monohydrate;
1-[(4-Fluorophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1H-indole dihydrochloride; and
1-[(4-Isopropylphenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1H-indole dihydrochloride.

4. The combination as claimed in any one of claims 1 to 3, wherein the NMDA receptor antagonist is memantine or a pharmaceutically acceptable salt thereof or wherein the NMDA receptor antagonist is memantine hydrochloride.

5. A combination comprising 1-[(2-Bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1H-indole dimesylate monohydrate and memantine hydrochloride.

6. The combination as claimed in any one of claims 1 to 5, for use in the treatment of cognitive disorders in a patient.

7. The combination as claimed in claim 6, wherein the cognitive disorders are selected from Alzheimer's disease, schizophrenia, Parkinson's disease, Lewy body dementia, vascular dementia and frontotemporal dementia.

8. A compound, 1-[(2-Bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl) methyl]-1H-indole or pharmaceutically acceptable salt thereof for use in combination with NMDA receptor antagonist or a pharmaceutically acceptable salt thereof for the treatment of Alzheimer's disease in a patient.

9. The compound for use as claimed in claim 8, as an adjunct treatment for Alzheimer's disease in a patient on stable treatment with NMDA receptor antagonist or a pharmaceutically acceptable salt thereof.

10. The compound for use as claimed in claim 8 or claim 9, wherein the NMDA receptor antagonist is memantine or a pharmaceutically acceptable salt thereof.

11. The compound for use as claimed in claim 8, wherein the 1-[(2-bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1H-indole or a pharmaceutically acceptable salt thereof is 1-[(2-Bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1H-indole dimesylate monohydrate.

12. The compound for use as claimed in claim 8 or claim 9,
(a) wherein 1 mg to 200 mg of 1-[(2-Bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1H-indole or a pharmaceutically acceptable salt thereof is to be administered to the patient per day, or
(b) wherein 1 mg to 10 mg of 1-[(2-Bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1H-indole or a pharmaceutically acceptable salt thereof is to be administered to the patient per day, or

(c) wherein 25 mg to 125 mg of 1-[(2-Bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1H-indole or a pharmaceutically acceptable salt thereof is to be administered to the patient per day, or
(d) wherein 150 mg to 200 mg of 1-[(2-Bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1H-indole or a pharmaceutically acceptable salt thereof is to be administered to the patient per day, or
(e) wherein 25 mg to 75 mg of 1-[(2-Bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1H-indole or a pharmaceutically acceptable salt thereof is to be administered to the patient per day, or
(f) wherein 75 mg to 150 mg of 1-[(2-Bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1H-indole or a pharmaceutically acceptable salt thereof is to be administered to the patient per day; and
(g) wherein 1 mg to 40 mg of memantine or a pharmaceutically acceptable salt thereof is to be administered to the patient per day, or
(h) wherein 5 mg to 28 mg memantine or a pharmaceutically acceptable salt thereof is to be administered to the patient per day.

13. The compound for use as claimed in claim 8 or claim 9, wherein the 1-[(2-Bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1H-indole or a pharmaceutically acceptable salt thereof is to be administered to the patient by oral, nasal, local, dermal or parenteral routes.

14. The compound for use as claimed in claim 8, wherein the 1-[(2-Bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1H-indole or a pharmaceutically acceptable salt thereof is to be administered to the patient one to three times per day, one to three times per week or one to three times per month.

15. A pharmaceutical composition comprising the combination as claimed in any one of claims 1 to 5, and pharmaceutically acceptable excipients or combination thereof.

16. The pharmaceutical composition as claimed in claim 15, for use in the treatment of cognitive disorder selected from Alzheimer's disease, schizophrenia, Parkinson's disease, Lewy body dementia, vascular dementia and frontotemporal dementia.

17. The pharmaceutical composition as claimed in claim 15 or claim 16,
(a) wherein the 1-[(2-Bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1H-indole or a pharmaceutically acceptable salt thereof is present in an amount of 1 mg to 300 mg, or
(b) wherein the 1-[(2-Bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1H-indole or a pharmaceutically acceptable salt thereof is present in an amount of 35 mg to 200 mg, or
(c) wherein the 1-[(2-Bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1H-indole or a pharmaceutically acceptable salt thereof is present in an amount of 200 mg to 300 mg, or
(d) wherein the 1-[(2-Bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1H-indole or a pharmaceutically acceptable salt thereof is present in an amount of 75 mg or 125 mg; and
(e) wherein the memantine or a pharmaceutically acceptable salt thereof is present in an amount of 5 mg to 40 mg.

18. Use of a combination as claimed in any one of claims 1 to 5 in the manufacture of a medicament for the treatment of cognitive disorders.

19. Use of a compound, 1-[(2-Bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl) methyl]-1H-indole or pharmaceutically acceptable salt thereof in combination with NMDA receptor antagonist or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of cognitive disorders.

20. Use of a pharmaceutical composition comprising the combination as claimed in any one of claims 1 to 5, and pharmaceutically acceptable excipients or combination thereof in the manufacture of a medicament for the treatment of cognitive disorders.